Currently, pancreatic adenocarcinoma mainly occurs after 60 years of age, and its prognosis
remains poor despite modest improvements in recent decades. The aging of the population …

Objectives To assess the impact of neural invasion/NI on overall survival/OS and tumor
recurrence in pancreatic ductal adenocarcinoma/PDAC. Summary background data NI is a …

Background. Multimodality treatment (MMT) improves survival for patients with pancreatic
ductal adenocarcinoma (PDAC). The surgery-first (SF) strategy is the most universally …

Adjuvant chemotherapy after pancreatoduodenectomy for pancreatic cancer is currently
considered standard of care. In this nationwide study, we investigated which characteristics …

By 2030 70% of newly diagnosed pancreatic ductal adenocarcinoma (PDAC) will occur in
older adults. Elderly patients, defined by the World Health Organization (WHO) as people …

Importance Patients 80 years and older with pancreatic ductal adenocarcinoma (PDAC)
have not consistently received treatments that have established benefits in younger older …

Background While the elderly population account for an indispensable proportion in
pancreatic ductal adenocarcinoma (PDAC), these patients are underrepresented in clinical …

Purpose In recent years, significant progress in survival has been achieved using systemic
combination chemotherapy in patients with pancreatic cancer. However, the elderly are …

The age at which patients are undergoing pancreatoduodenectomy is increasing worldwide.
The data on the outcome of this surgical procedure in the elderly is constantly expanding …

Background Multimodal therapy is recommended for early stage pancreatic cancer,
although whether all patients benefit and the optimal timing of chemotherapy remain …